Antipsychotic - patients NOT on the SMI register

Rationale: 1,2

NICE CG178 Psychosis and schizophrenia in adults: treatment and management

NICE CG155 Psychosis and schizophrenia in children and young people

Antipsychotic use may be associated with an increased risk of VTE. At present there are insufficient data available to determine any difference in risk between atypical and conventional antipsychotics, or between individual drugs. All possible risk factors for VTE should be identified before and during antipsychotic treatment and preventive measures undertaken

MHRA Drug safety update Volume 2 Issue 11 June 2009

Antipsychotic - patients NOT on the SMI register

Rationale 1,2

Antipsychotic use may be associated with an increased risk of VTE. At present there are insufficient data available to determine any difference in risk between atypical and conventional antipsychotics, or between individual drugs. All possible risk factors for VTE should be identified before and during antipsychotic treatment and preventive measures undertaken

NICE CG178 Psychosis and schizophrenia in adults: treatment and management

NICE CG 185 Assessment & Management of bipolar disorder

NICE CG155 Psychosis and schizophrenia in children and young people
1.1 Aripiprazole is recommended as an option for the treatment of schizophrenia in people aged 15 to 17 years who are intolerant of risperidone, or for whom risperidone is contraindicated, or whose schizophrenia has not been adequately controlled with risperidone.

1.2 People aged 15 to 17 years currently receiving aripiprazole for the treatment of schizophrenia who do not meet the criteria specified in 1.1 should have the option to continue treatment until it is considered appropriate to stop. This decision should be made jointly by the clinician and the person with schizophrenia, and if appropriate, their parents or carers.

NICE TA213 Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years January 2011

Antipsychotic use may be associated with an increased risk of VTE. At present there are insufficient data available to determine any difference in risk between atypical and conventional antipsychotics, or between individual drugs. All possible risk factors for VTE should be identified before and during antipsychotic treatment and preventive measures undertaken

MHRA Drug safety update Volume 2 Issue 11 June 2009

Antipsychotic - patients NOT on the SMI register

Rationale 1,2

NICE CG178 Psychosis and schizophrenia in adults: treatment and management

NICE CG155 Psychosis and schizophrenia in children and young people

Antipsychotic use may be associated with an increased risk of VTE. At present there are insufficient data available to determine any difference in risk between atypical and conventional antipsychotics, or between individual drugs. All possible risk factors for VTE should be identified before and during antipsychotic treatment and preventive measures undertaken

MHRA Drug safety update Volume 2 Issue 11 June 2009

Antipsychotic - patients NOT on the SMI register

Rationale 1,2

NICE CG178 Psychosis and schizophrenia in adults: treatment and management

Antipsychotic use may be associated with an increased risk of VTE. At present there are insufficient data available to determine any difference in risk between atypical and conventional antipsychotics, or between individual drugs. All possible risk factors for VTE should be identified before and during antipsychotic treatment and preventive measures undertaken

MHRA Drug safety update Volume 2 Issue 11 June 2009

Antipsychotic - patients NOT on the SMI register

Brand : Largactil

Rationale 1,2

NICE CG178 Psychosis and schizophrenia in adults: treatment and management

Antipsychotic use may be associated with an increased risk of VTE. At present there are insufficient data available to determine any difference in risk between atypical and conventional antipsychotics, or between individual drugs. All possible risk factors for VTE should be identified before and during antipsychotic treatment and preventive measures undertaken

MHRA Drug safety update Volume 2 Issue 11 June 2009

Antipsychotic - patients NOT on the SMI register

NICE CG178 Psychosis and schizophrenia in adults: treatment and management

NICE CG 185 Assessment & Management of bipolar disorder

NICE CG155 Psychosis and schizophrenia in children and young people

Antipsychotic use may be associated with an increased risk of VTE. At present there are insufficient data available to determine any difference in risk between atypical and conventional antipsychotics, or between individual drugs. All possible risk factors for VTE should be identified before and during antipsychotic treatment and preventive measures undertaken

MHRA Drug safety update Volume 2 Issue 11 June 2009

Antipsychotic - patients NOT on the SMI register

Rationale 1,2

NICE CG178 Psychosis and schizophrenia in adults: treatment and management

NICE CG155 Psychosis and schizophrenia in children and young people

Antipsychotic use may be associated with an increased risk of VTE. At present there are insufficient data available to determine any difference in risk between atypical and conventional antipsychotics, or between individual drugs. All possible risk factors for VTE should be identified before and during antipsychotic treatment and preventive measures undertaken

MHRA Drug safety update Volume 2 Issue 11 June 2009

Antipsychotic - patients NOT on the SMI register

Rationale 1,2

Antipsychotic use may be associated with an increased risk of VTE. At present there are insufficient data available to determine any difference in risk between atypical and conventional antipsychotics, or between individual drugs. All possible risk factors for VTE should be identified before and during antipsychotic treatment and preventive measures undertaken

MHRA Drug safety update Volume 2 Issue 11 June 2009

All new initiations of antipsychotics in patients with dementia should be undertaken by specialist services and once established to be effective and at a stable dose transferred to Primary care.

Doncaster & Bassetlaw Area Prescribing Committee March 2009

Antipsychotic - patients NOT on the SMI register

Brand : Invega

Rationale 1,2

Antipsychotic - patients NOT on the SMI register

Rationale 1,2

NICE CG178 Psychosis and schizophrenia in adults: treatment and management

NICE CG155 Psychosis and schizophrenia in children and young people

Antipsychotic use may be associated with an increased risk of VTE. At present there are insufficient data available to determine any difference in risk between atypical and conventional antipsychotics, or between individual drugs. All possible risk factors for VTE should be identified before and during antipsychotic treatment and preventive measures undertaken

MHRA Drug safety update Volume 2 Issue 11 June 2009

Antipsychotic - patients NOT on the SMI register

Rationale 1,2

NICE CG178 Psychosis and schizophrenia in adults: treatment and management

NICE CG155 Psychosis and schizophrenia in children and young people

Antipsychotic use may be associated with an increased risk of VTE. At present there are insufficient data available to determine any difference in risk between atypical and conventional antipsychotics, or between individual drugs. All possible risk factors for VTE should be identified before and during antipsychotic treatment and preventive measures undertaken

MHRA Drug safety update Volume 2 Issue 11 June 2009

Antipsychotic - patients NOT on the SMI register

Rationale: 1,2

NICE CG178 Psychosis and schizophrenia in adults: treatment and management

NICE CG155 Psychosis and schizophrenia in children and young people

Antipsychotic use may be associated with an increased risk of VTE. At present there are insufficient data available to determine any difference in risk between atypical and conventional antipsychotics, or between individual drugs. All possible risk factors for VTE should be identified before and during antipsychotic treatment and preventive measures undertaken

MHRA Drug safety update Volume 2 Issue 11 June 2009

Antipsychotic - patients NOT on the SMI register

Rationale: 1,2

Add-on treatment of major depressive episodes in patients with Major Depressive Disorder (MDD)

Antipsychotic use may be associated with an increased risk of VTE. At present there are insufficient data available to determine any difference in risk between atypical and conventional antipsychotics, or between individual drugs. All possible risk factors for VTE should be identified before and during antipsychotic treatment and preventive measures undertaken

MHRA Drug safety update Volume 2 Issue 11 June 2009

Antipsychotic - patients NOT on the SMI register

Rationale: 1,2

NICE CG113 Generalised anxiety disorder and panic disorder in adults: management

Revised SPCs: Atrolak (quetiapine fumarate) XL - SPC updated with warnings of increased risk of self-harm & suicide in patients 25- 64 yrs and increased risk of death in patients >65 years with Parkinson's disease/parkinsonism. Stroke added as an adverse effect of treatment (of unknown frequency).prolonged-release tablets - all strengths.

Antipsychotic - patients NOT on the SMI register

Rationale 1,2

NICE CG178 Psychosis and schizophrenia in adults: treatment and management

NICE CG 185 Assessment & Management of bipolar disorder

NICE CG155 Psychosis and schizophrenia in children and young people

Antipsychotic use may be associated with an increased risk of VTE. At present there are insufficient data available to determine any difference in risk between atypical and conventional antipsychotics, or between individual drugs. All possible risk factors for VTE should be identified before and during antipsychotic treatment and preventive measures undertaken

MHRA Drug safety update Volume 2 Issue 11 June 2009

Antipsychotic - patients NOT on the SMI register

Rationale 1,2

NICE CG178 Psychosis and schizophrenia in adults: treatment and management

NICE CG 185 Assessment & Management of bipolar disorder

Antipsychotic use may be associated with an increased risk of VTE. At present there are insufficient data available to determine any difference in risk between atypical and conventional antipsychotics, or between individual drugs. All possible risk factors for VTE should be identified before and during antipsychotic treatment and preventive measures undertaken

MHRA Drug safety update Volume 2 Issue 11 June 2009

Antipsychotic - patients NOT on the SMI register

Rationale 1,2

NICE CG178 Psychosis and schizophrenia in adults: treatment and management

NICE CG155 Psychosis and schizophrenia in children and young people

Antipsychotic use may be associated with an increased risk of VTE. At present there are insufficient data available to determine any difference in risk between atypical and conventional antipsychotics, or between individual drugs. All possible risk factors for VTE should be identified before and during antipsychotic treatment and preventive measures undertaken

MHRA Drug safety update Volume 2 Issue 11 June 2009

Antipsychotic - patients on the SMI register Antipsychotic use in dementia

Antipsychotic use may be associated with an increased risk of VTE. At present there are insufficient data available to determine any difference in risk between atypical and conventional antipsychotics, or between individual drugs. All possible risk factors for VTE should be identified before and during antipsychotic treatment and preventive measures undertaken

NICE CG178 Psychosis and schizophrenia in adults: treatment and management

NICE CG 185 Assessment & Management of bipolar disorder

NICE CG155 Psychosis and schizophrenia in children and young people

1.1 Aripiprazole is recommended as an option for the treatment of schizophrenia in people aged 15 to 17 years who are intolerant of risperidone, or for whom risperidone is contraindicated, or whose schizophrenia has not been adequately controlled with risperidone.

1.2 People aged 15 to 17 years currently receiving aripiprazole for the treatment of schizophrenia who do not meet the criteria specified in 1.1 should have the option to continue treatment until it is considered appropriate to stop. This decision should be made jointly by the clinician and the person with schizophrenia, and if appropriate, their parents or carers.

NICE TA213 Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years January 2011

Antipsychotic use may be associated with an increased risk of VTE. At present there are insufficient data available to determine any difference in risk between atypical and conventional antipsychotics, or between individual drugs. All possible risk factors for VTE should be identified before and during antipsychotic treatment and preventive measures undertaken

MHRA Drug safety update Volume 2 Issue 11 June 2009

Antipsychotic - patients on the SMI register - Antipsychotic use in dementia

NICE CG178 Psychosis and schizophrenia in adults: treatment and management

NICE CG155 Psychosis and schizophrenia in children and young people

Antipsychotic use may be associated with an increased risk of VTE. At present there are insufficient data available to determine any difference in risk between atypical and conventional antipsychotics, or between individual drugs. All possible risk factors for VTE should be identified before and during antipsychotic treatment and preventive measures undertaken

MHRA Drug safety update Volume 2 Issue 11 June 2009"

Review Date: 01/10/2024

Antipsychotic – patients on the SMI register

NICE CG178 Psychosis and schizophrenia in adults: treatment and management

NICE CG155 Psychosis and schizophrenia in children and young people

Antipsychotic use may be associated with an increased risk of VTE. At present there are insufficient data available to determine any difference in risk between atypical and conventional antipsychotics, or between individual drugs. All possible risk factors for VTE should be identified before and during antipsychotic treatment and preventive measures undertaken
MHRA Drug safety update Volume 2 Issue 11 June 2009

Antipsychotic - patients on the SMI register
Antipsychotic use in dementia

NICE CG178 Psychosis and schizophrenia in adults: treatment and management

NICE CG42 Dementia: supporting people with dementia and their carers in health and social care

Antipsychotic use may be associated with an increased risk of VTE. At present there are insufficient data available to determine any difference in risk between atypical and conventional antipsychotics, or between individual drugs. All possible risk factors for VTE should be identified before and during antipsychotic treatment and preventive measures undertaken

MHRA Drug safety update Volume 2 Issue 11 June 2009

Antipsychotic - patients on the SMI register

NICE CG178 Psychosis and schizophrenia in adults: treatment and management

Antipsychotic use may be associated with an increased risk of VTE. At present there are insufficient data available to determine any difference in risk between atypical and conventional antipsychotics, or between individual drugs. All possible risk factors for VTE should be identified before and during antipsychotic treatment and preventive measures undertaken

MHRA Drug safety update Volume 2 Issue 11 June 2009

Antipsychotic - patients on the SMI register
Antipsychotic use in dementia

NICE CG178 Psychosis and schizophrenia in adults: treatment and management

NICE CG42 Dementia: supporting people with dementia and their carers in health and social care

NICE CG 185 Assessment & Management of bipolar disorder

NICE CG155 Psychosis and schizophrenia in children and young people

Antipsychotic use may be associated with an increased risk of VTE. At present there are insufficient data available to determine any difference in risk between atypical and conventional antipsychotics, or between individual drugs. All possible risk factors for VTE should be identified before and during antipsychotic treatment and preventive measures undertaken

MHRA Drug safety update Volume 2 Issue 11 June 2009

Antipsychotic - patients on the SMI register
Antipsychotic use in dementia

NICE CG178 Psychosis and schizophrenia in adults: treatment and management

NICE CG155 Psychosis and schizophrenia in children and young people

Antipsychotic use may be associated with an increased risk of VTE. At present there are insufficient data available to determine any difference in risk between atypical and conventional antipsychotics, or between individual drugs. All possible risk factors for VTE should be identified before and during antipsychotic treatment and preventive measures undertaken

MHRA Drug safety update Volume 2 Issue 11 June 2009

Antipsychotic - patients on the SMI register
Antipsychotic use in dementia

NICE CG42 Dementia: supporting people with dementia and their carers in health and social care

Antipsychotic use may be associated with an increased risk of VTE. At present there are insufficient data available to determine any difference in risk between atypical and conventional antipsychotics, or between individual drugs. All possible risk factors for VTE should be identified before and during antipsychotic treatment and preventive measures undertaken

MHRA Drug safety update Volume 2 Issue 11 June 2009

All new initiations of antipsychotics in patients with dementia should be undertaken by specialist services and once established to be effective and at a stable dose transferred to Primary care.

Doncaster & Bassetlaw Area Prescribing Committee March 2009

Antipsychotic - patients on the SMI register

NICE CG178 Psychosis and schizophrenia in adults: treatment and management

Antipsychotic - patients on the SMI register

NICE CG178 Psychosis and schizophrenia in adults: treatment and management

NICE CG155 Psychosis and schizophrenia in children and young people

Antipsychotic use may be associated with an increased risk of VTE. At present there are insufficient data available to determine any difference in risk between atypical and conventional antipsychotics, or between individual drugs. All possible risk factors for VTE should be identified before and during antipsychotic treatment and preventive measures undertaken

MHRA Drug safety update Volume 2 Issue 11 June 2009

Antipsychotic - patients on the SMI register

NICE CG178 Psychosis and schizophrenia in adults: treatment and management

NICE CG155 Psychosis and schizophrenia in children and young people

Antipsychotic use may be associated with an increased risk of VTE. At present there are insufficient data available to determine any difference in risk between atypical and conventional antipsychotics, or between individual drugs. All possible risk factors for VTE should be identified before and during antipsychotic treatment and preventive measures undertaken

MHRA Drug safety update Volume 2 Issue 11 June 2009

Antipsychotic - patients on the SMI register      
Antipsychotic use in dementia

NICE CG178 Psychosis and schizophrenia in adults: treatment and management

NICE CG155 Psychosis and schizophrenia in children and young people

Antipsychotic use may be associated with an increased risk of VTE. At present there are insufficient data available to determine any difference in risk between atypical and conventional antipsychotics, or between individual drugs. All possible risk factors for VTE should be identified before and during antipsychotic treatment and preventive measures undertaken

MHRA Drug safety update Volume 2 Issue 11 June 2009

Antipsychotic - patients on the SMI register 

Antipsychotic - patients on the SMI register      
Antipsychotic use in dementia

NICE CG113 Generalised anxiety disorder and panic disorder in adults: management

Revised SPCs: Atrolak (quetiapine fumarate) XL - SPC updated with warnings of increased risk of self-harm & suicide in patients 25- 64yrs and increased risk of death in patients >65 years with Parkinson's disease/parkinsonism. Stroke added as an adverse effect of treatment (of unknown frequency).prolonged-release tablets - all strengths.

Antipsychotic - patients on the SMI register
Antipsychotic use in dementia

Antipsychotic use may be associated with an increased risk of VTE. At present there are insufficient data available to determine any difference in risk between atypical and conventional antipsychotics, or between individual drugs. All possible risk factors for VTE should be identified before and during antipsychotic treatment and preventive measures undertaken

MHRA Drug safety update Volume 2 Issue 11 June 2009

Prescribe orodispersible tablets only when patient has swallowing difficulties

Antipsychotic - patients on the SMI register

NICE CG178 Psychosis and schizophrenia in adults: treatment and management

NICE CG 185 Assessment & Management of bipolar disorder

NICE CG155 Psychosis and schizophrenia in children and young people

Antipsychotic use may be associated with an increased risk of VTE. At present there are insufficient data available to determine any difference in risk between atypical and conventional antipsychotics, or between individual drugs. All possible risk factors for VTE should be identified before and during antipsychotic treatment and preventive measures undertaken

MHRA Drug safety update Volume 2 Issue 11 June 2009

Antipsychotic - patients on the SMI register
Antipsychotic use in dementia

NICE CG178 Psychosis and schizophrenia in adults: treatment and management

NICE CG155 Psychosis and schizophrenia in children and young people

Antipsychotic use may be associated with an increased risk of VTE. At present there are insufficient data available to determine any difference in risk between atypical and conventional antipsychotics, or between individual drugs. All possible risk factors for VTE should be identified before and during antipsychotic treatment and preventive measures undertaken

MHRA Drug safety update Volume 2 Issue 11 June 2009

Bipolar Disorder management of stable condition

Brand : Depakote

Valproate (Belvo, Convulex, Depakote, Dyzantil, Epilim, Epilim Chrono or Chronosphere, Episenta, Epival, and Syonell▼): new safety and educational materials to support regulatory measures in men and women under 55 years of age click here

Update on MHRA review into safe use of valproate Click here

NICE CG 185 Assessment & Management of bipolar disorder

Antipsychotic - patients on the SMI register

NICE CG178 Psychosis and schizophrenia in adults: treatment and management

NICE CG155 Psychosis and schizophrenia in children and young people

Antipsychotic use may be associated with an increased risk of VTE. At present there are insufficient data available to determine any difference in risk between atypical and conventional antipsychotics, or between individual drugs. All possible risk factors for VTE should be identified before and during antipsychotic treatment and preventive measures undertaken

MHRA Drug safety update Volume 2 Issue 11 June 2009